A Placebo-controlled Randomized Clinical Trial of Naltrexone in the Context of Different Levels of Psychosocial Intervention
Overview
Authors
Affiliations
Background: Naltrexone is approved for the treatment of alcohol dependence when used in conjunction with a psychosocial intervention. This study was undertaken to examine the impact of 3 types of psychosocial treatment combined with either naltrexone or placebo treatment on alcohol dependency over 24 weeks of treatment: (1) Cognitive-Behavioral Therapy (CBT) + medication clinic, (2) BRENDA (an intervention promoting pharmacotherapy) + medication clinic, and (3) a medication clinic model with limited therapeutic content.
Methods: Two hundred and forty alcohol-dependent subjects were enrolled in a 24-week double-blind placebo-controlled study of naltrexone (100 mg/d). Subjects were also randomly assigned to 1 of 3 psychosocial interventions. All patients were assessed for alcohol use, medication adherence, and adverse events at regularly scheduled research visits.
Results: There was a modest main treatment effect for the psychosocial condition favoring those subjects randomized to CBT. Intent-to-treat analyses suggested that there was no overall efficacy of naltrexone and no medication by psychosocial intervention interaction. There was a relatively low level of medication adherence (50% adhered) across conditions, and this was associated with poor outcome.
Conclusions: Results from this 24-week treatment study demonstrate the importance of the psychosocial component in the treatment of alcohol dependence. Moreover, results demonstrate a substantial association between medication adherence and treatment outcomes. The findings suggest that further research is needed to determine the appropriate use of pharmacotherapy in maximizing treatment response.
Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis.
McPheeters M, OConnor E, Riley S, Kennedy S, Voisin C, Kuznacic K JAMA. 2023; 330(17):1653-1665.
PMID: 37934220 PMC: 10630900. DOI: 10.1001/jama.2023.19761.
Donoghue K, Boniface S, Brobbin E, Byford S, Coleman R, Coulton S Health Technol Assess. 2023; 27(22):1-88.
PMID: 37924307 PMC: 10641712. DOI: 10.3310/DQKL6124.
Margolis E, Moulton M, Lambeth P, OMeara M Neuropharmacology. 2022; 225:109376.
PMID: 36516892 PMC: 10548835. DOI: 10.1016/j.neuropharm.2022.109376.
van Amsterdam J, Blanken P, Spijkerman R, van den Brink W, Hendriks V Alcohol Alcohol. 2022; 57(6):768-775.
PMID: 36085572 PMC: 9651984. DOI: 10.1093/alcalc/agac043.
Mechanisms of quality-of-life improvement in treatment for alcohol use disorder.
Carlon H, Hurlocker M, Witkiewitz K J Consult Clin Psychol. 2022; 90(8):601-612.
PMID: 36066862 PMC: 9899433. DOI: 10.1037/ccp0000750.